ADDED
Our business could be adversely affected by economic downturns, inflation, changes in interest rates, natural disasters, public health crises, political crises, government shutdowns, geopolitical events or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition.
We rely on third parties in the supply and manufacture of our product candidates for our research, preclinical and clinical activities, and may do the same for commercial supplies of our product candidates.
Our failure to meet the continued listing requirements of the Nasdaq Capital Market ( Nasdaq ) could result in a delisting of our securities.
Overview We are a clinical stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with alopecia areata ( AA ) and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Bempikibart (ADX-914) Bempikibart (ADX-914), our most advanced product candidate, is a fully human anti interleukin-7 receptor alpha ( IL-7R ), antagonist monoclonal antibody designed to re-regulate adaptive immune function by potently blocking signaling mediated by interleukin-7 ( IL-7 ), and thymic stromal lymphopoietin ( TSLP ).
We have completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL-AA Part A, for the treatment of AA, and SIGNAL-AD, for the treatment of atopic dermatitis ( AD ).
In December 2024, we announced topline results from both of these trials, as well as our intention to advance bempikibart for the treatment of AA.
In April 2025, we announced dosing of the first patients in both the Part A open-label extension and Part B of the SIGNAL-AA Phase 2a clinical trial and in October 2025, we announced completion of enrollment in SIGNAL-AA Part B.
Bempikibart is being evaluated for the treatment of AA in the ongoing Part B of the SIGNAL-AA Phase 2a clinical trial.
Enrollment has been completed in the Part B portion of the clinical trial, with 33 patients enrolled, and dosing remains ongoing.
REMOVED
Our strategic refocus and the associated workforce reduction announced in February 2025 may not result in anticipated cost savings, could result in total costs and expenses that are greater than expected and could disrupt our business.
Merger with Homology On March 25, 2024, Q32 Bio Inc., a Delaware corporation (previously named Homology Medicines, Inc., a Delaware corporation and our predecessor company, or Homology), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of November 16, 2023, or the Merger Agreement, by and among Homology, Kenobi Merger Sub, Inc., or Merger Sub, and Q32 Bio Operations Inc.
Pursuant to the Merger Agreement, on the Closing Date, (i) Homology effected a reverse stock split of Homology s issued common stock at a ratio of 1:18, or the Reverse Stock Split, (ii) Homology changed its name to Q32 Bio Inc., and (iii) Merger Sub merged with and into Legacy Q32, or the Merger, with Legacy Q32 as the surviving company in the Merger and, after giving effect to such Merger, Legacy Q32 becoming a wholly-owned subsidiary of Q32 Bio Inc., or together with its consolidated subsidiaries, Q32, the Company, we or us.
As of the open of trading on March 26, 2024, our common stock began trading on the Nasdaq Global Market, or Nasdaq, under the symbol QTTB.
Overview We are a clinical stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction.
To achieve this goal of restoring homeostasis to a dysregulated immune system, we are advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive and innate immunity.
The adaptive immune system is largely composed of T- and B-cell mediated cellular and antibody responses; while the innate immune system is a first line of defense employing leukocytes such as monocytes, macrophages, neutrophils, dendritic cells and natural killer cells that are responsible for clearing pathogens and cellular debris, and modulating T- and B-cell function.
We believe that targeting these key pathways of immune dysregulation in autoimmune and inflammatory diseases will deliver therapeutics for indications with clear unmet medical need in the near term, while enabling us to build a broad and diverse pipeline in the long term.
We have multiple product candidates across a variety of autoimmune and inflammatory diseases.
Bempikibart (ADX-914), our most advanced product candidate, is a fully human anti interleukin-7 receptor alpha, or IL-7R , antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7, or IL-7, and thymic stromal lymphopoietin, or TSLP.